Foster C. Gonsalves

Foster C. Gonsalves

Auto-generated profile, based on publicly available information

Foster C. Gonsalves

Inspirna Inc. 2 , New York, NY

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2026 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
PDF file
BOBenjamin N. Ostendorf
Benjamin N. Ostendorf
JGJonathan G. Goldstein
Jonathan G. Goldstein
SLShuang Liu
Shuang Liu
FGFoster C. Gonsalves
Foster C. Gonsalves
JBJana Bilanovic
Jana Bilanovic
STSohail F. Tavazoie
Sohail F. Tavazoie
Many cancer patients do not benefit from current immunotherapies. This lack of efficacy may be, in part, due to insufficient priming and activation of T cells. Here, we show that activation of liver-X-receptors (LXRs) promotes adaptive anti-tumor immunity by enhancing priming of T cells. Genetic LXR deletion in the host and depletion of dendritic and CD8+ T cells, but not of macrophages, abrogated anti-tumor effects of LXR-agonistic therapy. In cross-presentation assays, LXR agonism promoted T cell activation upon DC/T cell cross talk. Genetic deletion of LXRs in T cells, but not in dendritic cells, blunted this effect. Dissection of the temporal dynamics of LXR-enhanced T cell effector function showed that LXR agonism rendered T cells more receptive to adopting effector states upon stimulation. Consistently, LXR agonist therapy elicited T cell expansion in cancer patients enrolled in a phase I trial. Our findings establish LXR activation as an effective approach for enhancing T cell priming.